Home › Nierkanker › New York › New York City
Nierkanker klinische studies in New York City, NY
15 studies voor Nierkanker zoeken deelnemers op locaties in en rond New York City (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RekruterenFase 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RekruterenFase 1
- NEO-811 NYC Site, New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RekruterenFase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RekruterenFase 3
- Research Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruterenObservatieonderzoek
- NYU Langone Medical Center, New York
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekruterenFase 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- en nog 1
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RekruterenFase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruterenFase 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Study of a Side Effects and Resource Navigation Program for People With Cancer
Rekruteren
- City College of New York (Data Collection AND Specimen Analysis), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Brodalumab in the Treatment of Immune-Related Adverse Events
RekruterenFase 1
- Columbia University Irving Medical Center, New York
Kidney Cancer DNA Registry
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Memorial Sloan Kettering Cancer Center, New York
Decision Aid (DA) for Renal Patients
Rekruteren
- NYU Langone Health, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruterenFase 1/2
- NYU Langone Health, New York
Nierkanker studies in andere steden
- Nashville, TN12 studies
- Boston, MA12 studies
- Houston, TX10 studies
- San Diego, CA9 studies
- St. Louis, MO9 studies
- Dallas, TX9 studies
- Washington, DC9 studies
- Seattle, WA8 studies
- Edison, NJ8 studies
- Miami, FL8 studies
- Los Angeles, CA7 studies
- Rochester, MN7 studies
Andere studies in New York City
- Borstkanker136 studies
- Niet-kleincellige longkanker121 studies
- Kanker (alle vormen)109 studies
- Prostaatkanker103 studies
- Metastatische kanker93 studies
- Colorectale kanker78 studies
- Eierstokkanker69 studies
- Longkanker60 studies
- Multipel myeloom60 studies
- Aldermeesklierkanker60 studies
- Endometriumkanker52 studies
- Acute myeloïde leukemie51 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.